Strategic Focus Clinical-stage biotech targeting cellular metabolism for anti-fibrotic and anti-tumor therapies, presenting opportunities to partner on late-stage or combination trials with metabolic inhibitors and oncology/fibrosis focus.

Lead Asset Potency IM156 as a first potent PC1 inhibitor in OXPHOS pathway with Phase 1 completed and plans for Phase 2 PoC in IPF, signaling potential for co-development or licensing discussions with larger pharma seeking novel metabolism-targeting therapies.

Financing Trajectory Recent financing rounds including Series B expansions and notable milestones indicate a viable path for strategic collaborations, co-investments, or milestone-driven partnerships to accelerate clinical development.

Clinical Milestones Progress in Phase 1 healthy volunteer studies and early Phase 1b doses in combination regimens for pancreatic cancer demonstrates openness to combination therapies, creating sales angles with diagnostic or companion diagnostic firms.

Industry Alignment Biotech sits at the intersection of metabolism, oncology, and fibrosis with alignments to both big pharma and specialized biotech networks; potential fit for research collaborations, CRO/CMO services, or access to manufacturing and regulatory strategy support.